<DOC>
	<DOCNO>NCT01663532</DOCNO>
	<brief_summary>The primary purpose study evaluate overall efficacy aripiprazole intramuscular ( IM ) depot acute treatment subject schizophrenia . The secondary purpose evaluate safety tolerability aripiprazole IM depot administer every 4 week 12 week adult subject schizophrenia .</brief_summary>
	<brief_title>Trial Aripiprazole Intramuscular Depot ( OPC-14597 , Lu AF41155 ) Acute Treatment Adults With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Male female subject 18 65 year age , inclusive , time informed consent . Subjects diagnosis schizophrenia least 1 year define DSMIVTR criterion confirm MINI Schizophrenia Psychotic Disorders Studies . Subjects stable living environment hospital . Subjects would benefit hospitalization continue hospitalization treatment current acute relapse schizophrenia trial entry . Subjects experience acute exacerbation psychotic symptom mark deterioration usual function demonstrate meet BOTH follow screen baseline : Currently experience acute exacerbation psychotic symptom accompany significant deterioration subject 's clinical and/or functional status baseline clinical presentation Positive Negative Syndrome Scale ( PANSS ) Total Score ≥ 80 AND Specific psychotic symptom PANSS measure score &gt; 4 follow item ( possible score 1 7 item ) Conceptual disorganization ( P2 ) Hallucinatory behavior ( P3 ) Suspiciousness/persecution ( P6 ) Unusual thought content ( G9 ) Subjects receive previous outpatient antipsychotic treatment adequate dose adequate duration show previous good response antipsychotic treatment ( clozapine ) last 12 month . Subjects history relapse and/or exacerbation symptom receive antipsychotic treatment , exclude current episode . Subjects willing discontinue prohibit psychotropic medication meet protocol require washout prior trial period . BMI less ≤ 40 kg/m2 ( morbid obesity ) screening . Subjects able provide write informed consent . Ability understand nature trial follow protocol requirement . Sexually active male childbearing potential agree practice 2 different method birth control remain abstinent trial 180 day last dose trial medication . Sexually active female childbearing potential agree practice 2 different method birth control remain abstinent trial 150 day last dose trial medication . Females breastfeed and/or positive pregnancy test result prior receive IMP trial . Subjects improvement ≥ 30 % total PANSS score screen baseline assessment . Subjects present first episode schizophrenia Subjects hospitalize ≥ 30 day last 90 day prior screen visit . Subjects hospitalize &gt; 5 day current acute episode time screen visit Subjects schizophrenia consider resistant/refractory antipsychotic treatment Subjects history response clozapine treatment . Subjects current DSMIVTR Axis I diagnosis schizophrenia Also , subject borderline , paranoid , histrionic , schizotypal , schizoid , antisocial personality disorder mental retardation . Subjects experience acute depressive symptom within past 30 day require treatment antidepressant . Subjects significant risk violent behavior ; represent risk commit suicide indicate suicidal ideation within last 1 month suicidal behavior within last year ; present serious risk suicide . Subjects clinically significant tardive dyskinesia , . Subjects severe akathisia . Subjects meet DSMIVTR criterion substance abuse past 3 month prior screen dependence within past 6 month ; include alcohol benzodiazepine , exclude caffeine nicotine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>